argenex’s (ARGX) “Neutral” Rating Reiterated at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reaffirmed their neutral rating on shares of argenex (NASDAQ:ARGX) in a report published on Friday morning.

Several other equities analysts have also recently commented on the stock. Piper Sandler upped their target price on shares of argenex from $1,075.00 to $1,215.00 and gave the company an “overweight” rating in a research note on Monday, August 17th. Robert W. Baird decreased their price target on shares of argenex from $932.00 to $823.00 and set a “neutral” rating on the stock in a research report on Friday. Citizens Jmp boosted their price objective on shares of argenex from $932.00 to $1,200.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 18th. HC Wainwright boosted their price objective on shares of argenex from $940.00 to $1,202.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Finally, Weiss Ratings lowered shares of argenex from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,158.32.

argenex Stock Down 1.1%

Shares of ARGX stock traded down $8.73 during trading hours on Friday, reaching $816.29. 116,667 shares of the company’s stock were exchanged, compared to its average volume of 345,069. argenex has a fifty-two week low of $661.85 and a fifty-two week high of $1,072.75. The stock has a market capitalization of $51.07 billion, a P/E ratio of 31.35, a P/E/G ratio of 0.86 and a beta of 0.44. The business has a fifty day moving average price of $959.93 and a 200-day moving average price of $877.49.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.86 by $1.46. The business had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.45 billion. argenex had a net margin of 32.19% and a return on equity of 43.59%. As a group, research analysts expect that argenex will post 28.83 EPS for the current fiscal year.

Institutional Trading of argenex

Several hedge funds have recently modified their holdings of ARGX. GAMMA Investing LLC raised its position in argenex by 31.5% in the 3rd quarter. GAMMA Investing LLC now owns 459 shares of the company’s stock valued at $440,000 after purchasing an additional 110 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in argenex by 3.6% in the third quarter. Farther Finance Advisors LLC now owns 378 shares of the company’s stock valued at $363,000 after acquiring an additional 13 shares during the last quarter. Valeo Financial Advisors LLC increased its position in argenex by 6.2% in the third quarter. Valeo Financial Advisors LLC now owns 1,144 shares of the company’s stock worth $1,097,000 after purchasing an additional 67 shares during the period. QRG Capital Management Inc. lifted its position in argenex by 24.6% during the 2nd quarter. QRG Capital Management Inc. now owns 1,907 shares of the company’s stock valued at $1,769,000 after purchasing an additional 377 shares during the period. Finally, Envestnet Portfolio Solutions Inc. lifted its position in argenex by 12.7% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 365 shares of the company’s stock valued at $339,000 after purchasing an additional 41 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

About argenex

argenx SE (NASDAQ:ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company combines antibody engineering technologies with disease biology to discover medicines that target the underlying mechanisms of immune-mediated disorders.

argenx’s leading product is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo in the United States. The therapies are designed to reduce disease-causing immunoglobulin G (IgG) antibodies by targeting the neonatal Fc receptor (FcRn).